Skip to Content

Enfortumab Vedotin as Neoadjuvant Treatment for MIBC

Patients with muscle-invasive bladder cancer (MIBC), who are cisplatin-ineligible, show promising antitumor activity with enfortumab vedotin monotherapy as neoadjuvant treatment. That is the conclusion from a newly published study presented by MD and Professor Daniel Petrylak in this MEDtalk.

Daniel Petrylak

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top